Skip to NavigationSkip to content

DVT

NICE wants more information on Xarelto

Xarelto picture

NICE is asking Bayer for more information about its blood thinner Xarelto in new guidance. 

The watchdog is currently minded not to recommend Xarelto (rivaroxaban) for the treatment of deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism (PE), following an acute DVT.

NICE said Bayer will need to provide further evidence relating to Xarelto’s clinical and cost effectiveness, specially relating to its long-term efficacy. 

Bayer submits new Xarelto indications for European approval

Bayer's Xarelto (rivaroxaban)

Bayer is seeking European regulatory approval for a batch of new indications for its oral anticoagulant Xarelto.

The company is looking to expand the drug’s licenced indications to include stroke prevention in patients with atrial fibrillation, the treatment of deep vein thrombosis (DVT) and the prevention of recurrent DVT and pulmonary embolism.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches